1
|
Pérez EM, Torbay AG, López MS, de la Cámara RCM, Jiménez CR, Álvarez MÁM, Blanco JN, Gianelli C, Hijón CC, Granados EL, Pena RR, Del Pozo Mate Á, García-Morato MB. Genetics of inborn errors of immunity: Diagnostic strategies and new approaches to CNV detection. Eur J Clin Invest 2024; 54:e14191. [PMID: 38440843 DOI: 10.1111/eci.14191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 02/20/2024] [Accepted: 02/25/2024] [Indexed: 03/06/2024]
Abstract
BACKGROUND Genetic diagnosis of inborn errors of immunity (IEI) is complex due to the large number of genes involved and their molecular features. Missense variants have been reported as the most common cause of IEI. However, the frequency of copy number variants (CNVs) may be underestimated since their detection requires specific quantitative techniques. At this point, the use of Next Generation Sequencing (NGS) is acquiring relevance. METHODS In this article, we present our experience in the genetic diagnosis of IEI based on three diagnostic algorithms that allowed the detection of single nucleotide variants (SNVs) and CNVs. Following this approximation, 703 index cases were evaluated between 2014 and 2021. Sanger sequencing, MLPA, CGH array, breakpoint spanning PCR or a customized NGS-based multigene-targeted panel were performed. RESULTS A genetic diagnosis was reached in 142 of the 703 index cases (20%), 19 of them presented deletions as causal variants. Deletions were also detected in 5 affected relatives and 16 healthy carriers during the family studies. Additionally, we compile, characterize and present all the CNVs detected by our diagnostic algorithms, representing the largest cohort of deletions related to IEI to date. Furthermore, three bioinformatic tools (LACONv, XHMM, VarSeq™) based on NGS data were evaluated. VarSeq™ was the most sensitive and specific bioinformatic tool; detecting 21/23 (91%) deletions located in captured regions. CONCLUSION Based on our results, we propose a strategy to guide the molecular diagnosis that can be followed by expert and non-expert centres in the field of IEI.
Collapse
Affiliation(s)
| | | | - Mario Solis López
- Bioinformatics Section, Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, La Paz University Hospital, UAM, Madrid, Spain
| | | | - Carmen Rodríguez Jiménez
- Metabolic Disease Section, Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, La Paz University Hospital, Madrid, Spain
- Group of Dislipemias of genetic origin and metabolic diseases, IdiPAZ, La Paz University Hospital, Madrid, Spain
| | - Mari Ángeles Mori Álvarez
- Functional and Structural Genomics Section, Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases, Madrid, Spain
| | - Julián Nevado Blanco
- Functional and Structural Genomics Section, Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases, Madrid, Spain
| | - Carla Gianelli
- Immunology Department, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain
- La Paz Institute of Biomedical Research, Madrid, Spain
| | | | - Eduardo López Granados
- Immunology Department, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain
- La Paz Institute of Biomedical Research, Madrid, Spain
| | - Rebeca Rodríguez Pena
- Immunology Department, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain
- La Paz Institute of Biomedical Research, Madrid, Spain
| | - Ángela Del Pozo Mate
- Bioinformatics Section, Institute of Medical and Molecular Genetics (INGEMM)-IdiPAZ, La Paz University Hospital, UAM, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases, Madrid, Spain
- ERN-ITHACA, La Paz University Hospital, Madrid, Spain
| | - María Bravo García-Morato
- Immunology Department, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain
- La Paz Institute of Biomedical Research, Madrid, Spain
| |
Collapse
|
2
|
Valdivieso Shephard JL, Alvarez Robles EJ, Cámara Hijón C, Hernandez Breijo B, Novella-Navarro M, Bogas Schay P, Cuesta de la Cámara R, Balsa Criado A, López Granados E, Plasencia Rodríguez C. Predicting anti-TNF treatment response in rheumatoid arthritis: An artificial intelligence-driven model using cytokine profile and routine clinical practice parameters. Heliyon 2024; 10:e22925. [PMID: 38163219 PMCID: PMC10754867 DOI: 10.1016/j.heliyon.2023.e22925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Revised: 11/18/2023] [Accepted: 11/22/2023] [Indexed: 01/03/2024] Open
Abstract
Introduction Rheumatoid arthritis (RA) is a heterogeneous disease in which therapeutic strategies used have evolved dramatically. Despite significant progress in treatment strategies such as the development of anti-TNF drugs, it is still not possible to differentiate those patients who will respond from who will not. This can lead to effective-treatment delays and unnecessary costs. The aim of this study was to utilize a profile of the patient's characteristics, clinical parameters, immune status (cytokine profile) and artificial intelligence to assess the feasibility of developing a tool that could allow us to predict which patients will respond to treatment with anti-TNF drugs. Methods This study included 38 patients with RA from the RA-Paz cohort. Clinical activity was measured at baseline and after 6 months of treatment. The cytokines measured before the start of anti-TNF treatment were IL-1, IL-12, IL-10, IL-2, IL-4, IFNg, TNFa, and IL-6. Statistical analyses were performed using the Wilcoxon-Rank-Sum Test and the Benjamini-Hochberg method. The predictive model viability was explored using the 5-fold cross-validation scheme in order to train the logistic regression models. Results Statistically significant differences were found in parameters such as IL-6, IL-2, CRP and DAS-ESR. The predictive model performed to an acceptable level in correctly classifying patients (ROC-AUC 0.804167 to 0.891667), suggesting that it would be possible to develop a clinical classification tool. Conclusions Using a combination of parameters such as IL-6, IL-2, CRP and DAS-ESR, it was possible to develop a predictive model that can acceptably discriminate between remitters and non-remitters. However, this model needs to be replicated in a larger cohort to confirm these findings.
Collapse
Affiliation(s)
| | | | | | - Borja Hernandez Breijo
- Immunology-Rheumatology Research Group, Hospital Universitario La Paz-Idipaz, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
3
|
Turnbull C, Bones J, Stanley M, Medhavy A, Wang H, Lorenzo AMD, Cappello J, Shanmuganandam S, Pandey A, Seneviratne S, Brown GJ, Meng X, Fulcher D, Burgio G, Man SM, de Lucas Collantes C, Gasior M, López Granados E, Martin P, Jiang SH, Cook MC, Ellyard JI, Athanasopoulos V, Corry B, Canete PF, Vinuesa CG. DECTIN-1: A modifier protein in CTLA-4 haploinsufficiency. Sci Adv 2023; 9:eadi9566. [PMID: 38055819 PMCID: PMC10699772 DOI: 10.1126/sciadv.adi9566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Accepted: 11/06/2023] [Indexed: 12/08/2023]
Abstract
Autosomal dominant loss-of-function (LoF) variants in cytotoxic T-lymphocyte associated protein 4 (CTLA4) cause immune dysregulation with autoimmunity, immunodeficiency and lymphoproliferation (IDAIL). Incomplete penetrance and variable expressivity are characteristic of IDAIL caused by CTLA-4 haploinsufficiency (CTLA-4h), pointing to a role for genetic modifiers. Here, we describe an IDAIL proband carrying a maternally inherited pathogenic CTLA4 variant and a paternally inherited rare LoF missense variant in CLEC7A, which encodes for the β-glucan pattern recognition receptor DECTIN-1. The CLEC7A variant led to a loss of DECTIN-1 dimerization and surface expression. Notably, DECTIN-1 stimulation promoted human and mouse regulatory T cell (Treg) differentiation from naïve αβ and γδ T cells, even in the absence of transforming growth factor-β. Consistent with DECTIN-1's Treg-boosting ability, partial DECTIN-1 deficiency exacerbated the Treg defect conferred by CTL4-4h. DECTIN-1/CLEC7A emerges as a modifier gene in CTLA-4h, increasing expressivity of CTLA4 variants and acting in functional epistasis with CTLA-4 to maintain immune homeostasis and tolerance.
Collapse
Affiliation(s)
- Cynthia Turnbull
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Josiah Bones
- Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Maurice Stanley
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Arti Medhavy
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Hao Wang
- The Francis Crick Institute, London, UK
| | - Ayla May D. Lorenzo
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Jean Cappello
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Somasundhari Shanmuganandam
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Abhimanu Pandey
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Sandali Seneviratne
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Grant J Brown
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Xiangpeng Meng
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - David Fulcher
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Gaetan Burgio
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Si Ming Man
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | | | - Mercedes Gasior
- Hematology Department, Hospital Universitario La Paz, Madrid, Spain
| | - Eduardo López Granados
- Clinical Immunology Department, Hospital Universitario La Paz, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases, Madrid, Spain
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research, Madrid, Spain
| | - Pilar Martin
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Centro de Investigacion Biomedica En Rad, Madrid, Spain
| | - Simon H. Jiang
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Matthew C. Cook
- Cambridge Institute for Therapeutic Immunology and Infectious Diseases, University of Cambridge, Cambridge, UK
| | - Julia I. Ellyard
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Vicki Athanasopoulos
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Ben Corry
- Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia
| | - Pablo F. Canete
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
- Frazer Institute, The University of Queensland, Woolloongabba, Queensland, Australia
| | - Carola G. Vinuesa
- John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
- The Francis Crick Institute, London, UK
| |
Collapse
|
4
|
del Pino Molina L, Bravo Gallego LY, Nozal P, Soto-Serrano Y, Martínez-Feito A, Reche-Yebra K, González-Torbay A, Cuesta-Martín de la Cámara R, Gianelli C, Cámara C, González-García J, González-Muñoz M, Rodríguez-Pena R, López Granados E. Detection of specific RBD + IgG + memory B cells by flow cytometry in healthcare workers and patients with inborn errors of immunity after BNT162b2 m RNA COVID-19 vaccination. Front Immunol 2023; 14:1136308. [PMID: 37215146 PMCID: PMC10192857 DOI: 10.3389/fimmu.2023.1136308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Accepted: 04/13/2023] [Indexed: 05/24/2023] Open
Abstract
Introduction Inborn errors of immunity (IEI) are a heterogeneous group of diseases caused by intrinsic defects of the immune system. Estimating the immune competence of immunocompromised patients for an infection risk assessment or after SARS-CoV-2 vaccination constituted a challenge. Methods The aim of this study was to determine the humoral responses of patients with IEI through a comprehensive analysis of specific receptor-binding domain-positive (RBD+) IgG+ memory B cells (MBCs) by flow cytometry, together with routine S-specific IgG antibodies and QuantiFERON SARS-CoV-2 (T-cell response), before the vaccine and 3 weeks after a second dose. Results and discussion We first analyzed the percentage of specific RBD+ IgG+ MBCs in healthy healthcare workers. Within the control group, there was an increase in the percentage of specific IgG+ RBD+ MBCs 21 days after the second dose, which was consistent with S-specific IgG antibodies.Thirty-one patients with IEI were included for the pre- and post-vaccination study; IgG+ RBD+ MBCs were not evaluated in 6 patients due to an absence of B cells in peripheral blood. We detected various patterns among the patients with IEI with circulating B cells (25, 81%): an adequate humoral response was observed in 12/25, consider by the detection of positive S-specific IgG antibodies and the presence of specific IgG+ RBD+ MBCs, presenting a positive T-cell response; in 4/25, very low S-specific IgG antibody counts correlated with undetectable events in the IgG+ RBD+ MBC compartment but with positive cellular response. Despite the presence of S-specific IgG antibodies, we were unable to detect a relevant percentage of IgG+ RBD+ MBCs in 5/25; however, all presented positive T-cell response. Lastly, we observed a profound failure of B and T-cell response in 3 (10%) patients with IEI, with no assessment of S-specific IgG antibodies, IgG+ RBD+ MBCs, and negative cellular response. The identification of specific IgG+ RBD+ MBCs by flow cytometry provides information on different humoral immune response outcomes in patients with IEI and aids the assessment of immune competence status after SARS-CoV-2 mRNA vaccine (BNT162b2), together with S-specific IgG antibodies and T-cell responses.
Collapse
Affiliation(s)
- Lucía del Pino Molina
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | - Luz Yadira Bravo Gallego
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | - Pilar Nozal
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER U754), ISCIII, Madrid, Spain
- Complement Research Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | - Yolanda Soto-Serrano
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | - Ana Martínez-Feito
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
- Immuno-Rheumatology Research Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | - Keren Reche-Yebra
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | | | | | - Carla Gianelli
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
| | - Carmen Cámara
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
| | - J. González-García
- HIV Unit, Internal Medicine Department, La Paz University Hospital, AIDS and Infectious Diseases Group, Center for Biomedical Network Research on Infectious Diseases (CIBERINFEC CB21/13/00039), La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
| | | | - Rebeca Rodríguez-Pena
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
| | - Eduardo López Granados
- Center for Biomedical Network Research on Rare Diseases (CIBERER U767), ISCIII, Madrid, Spain
- Lymphocyte Pathophysiology in Immunodeficiencies Group, La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
- Clinical Immunology Department, La Paz University Hospital, Madrid, Spain
| |
Collapse
|
5
|
Al-Akioui Sanz K, Echecopar Parente C, Ferreras C, Menéndez Ribes M, Navarro A, Mestre C, Clares L, Vicario JL, Balas A, De Paz R, López Granados E, Sánchez Zapardiel E, Jiménez C, López-Oliva M, Ramos E, Hernández-Oliveros F, Pérez-Martínez A. Familial CD45RA - T cells to treat severe refractory infections in immunocompromised patients. Front Med (Lausanne) 2023; 10:1083215. [PMID: 36844219 PMCID: PMC9944023 DOI: 10.3389/fmed.2023.1083215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 01/13/2023] [Indexed: 02/10/2023] Open
Abstract
Background Immunocompromised patients are susceptible to high-risk opportunistic infections and malignant diseases. Most antiviral and antifungal drugs are quite toxic, relatively ineffective, and induce resistance in the long term. The transfer of pathogen-specific Cytotoxic T-Lymphocytes has shown a minimal toxicity profile and effectiveness in treating Cytomegalovirus, Adenovirus, Epstein - Barr virus, BK Virus and Aspergillus infections, but this therapy have the main limitations of regulatory issues, high cost, and absence of public cell banks. However, CD45RA- cells containing pathogen-specific memory T-cells involve a less complex manufacturing and regulatory process and are cheaper, feasible, safe, and potentially effective. Methods We present preliminary data from six immunocompromised patients: four who had severe infectious diseases and two who had EBV lymphoproliferative disease. All of them underwent multiple safe familial CD45RA- T-cell infusions as adoptive passive cell therapy, containing Cytomegalovirus, Epstein - Barr virus, BK virus, and Aspergillus-specific memory T-cells. We also present the method for selecting the best donors for CD45RA- cells in each case and the procedure to isolate and store these cells. Results The infusions were safe, there was no case of graft-versus host disease, and they showed a clear clinical benefit. The patients treated for BK virus nephritis, Cytomegalovirus encephalitis, Cytomegalovirus reactivation, and disseminated invasive aspergillosis experienced pathogen clearance, complete resolution of symptoms in 4-6 weeks and a lymphocyte increase in 3 of 4 cases after 3-4 months. Donor T cell transient microchimerism was detected in one patient. The two patients treated for EBV lymphoproliferative disease underwent chemotherapy and several infusions of CD45RA- memory T-cells containing EBV cytotoxic lymphocytes. Donor T-cell microchimerism was observed in both patients. The viremia cleared in one of the patients, and in the other, despite the viremia not clearing, hepatic lymphoproliferative disease remained stable and was ultimately cured with EBV-specific Cytotoxic T-Lymphocytes. Conclusion The use of familial CD45RA- T-cells containing specific Cytotoxic T-lymphocytes is a feasible, safe and potential effective approach for treating severe pathogen infections in immunocompromised patients through a third party donor. Furthermore, this approach might be of universal use with fewer institutional and regulatory barriers.
Collapse
Affiliation(s)
| | | | | | | | - Alfonso Navarro
- Hospital La Paz Institute for Health Research, Madrid, Spain
| | - Carmen Mestre
- Hospital La Paz Institute for Health Research, Madrid, Spain
| | - Laura Clares
- Hospital La Paz Institute for Health Research, Madrid, Spain
| | - José Luis Vicario
- Histocompatibility Unit, Transfusion Center of Madrid, Madrid, Spain
| | - Antonio Balas
- Histocompatibility Unit, Transfusion Center of Madrid, Madrid, Spain
| | - Raquel De Paz
- Cell Therapy Unit, Department of Hematology, La Paz University Hospital, Madrid, Spain
| | | | | | - Carlos Jiménez
- Department of Nephrology, La Paz University Hospital, Madrid, Spain
| | | | - Esther Ramos
- Intestinal Rehabilitation Unit, Pediatric Gastroenterology and Nutrition Unit, La Paz University Hospital, Madrid, Spain
| | | | - Antonio Pérez-Martínez
- Hospital La Paz Institute for Health Research, Madrid, Spain,Department of Pediatric Hemato-Oncology, La Paz University Hospital, Madrid, Spain,Department of Pediatrics, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain,*Correspondence: Antonio Pérez-Martínez,
| |
Collapse
|
6
|
Luque J, Mendes I, Gómez B, Morte B, Heredia ML, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch R, Fillat C, Pérez‐Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, Lapunzina P, Aguado C, Aguado C, Albiñana V, Alías L, Almoguera B, Alonso J, Alonso‐Ferreira V, Alvarez‐Mora MI, Alvarez‐Mora MI, Antiñolo G, Arbones ML, Arenas J, Arjona E, Armangue T, Armstrong J, Arnedo M, Artuch R, Masó AA, Avila‐Fernandez A, Ayuso C, Badell I, Badenas C, Baeza ML, Baiget M, Balcells S, Ballesta‐Martínez MJ, Barahona M, Barros F, Bartoccioni PC, Bayona‐Bafaluy MP, Sanz SB, Bernabéu C, Bernal S, Blanco‐Kelly F, Blázquez A, Bodoy S, Bogliolo M, Borralleras C, Borrego S, Botella LM, Pieri FB, Bovolenta P, Bravo‐Gil N, Brea A, Bueno‐Lozano G, Bueren J, Bustamante A, Caballero T, Camacho‐Macorra C, Cámara Y, Camats‐Tarruella N, Barrio ÁC, Campuzano V, Cantarero L, Cantó J, Caparrós‐Martín JA, Cardellach F, Carmona R, Carracedo Á, Carretero M, Casado M, Casado JA, Casasnovas C, Cascón A, Casino P, Castaño L, Castilla‐Vallmanya L, Catala A, Cayuela ML, Cediel R, Cervera J, Codina‐Solà M, Contreras J, Cormand B, Corominas R, Corral J, Corrochano V, Cortés‐Rodríguez A, Corton M, Costa‐Roger M, Cozar M, Crespo I, Crispi F, Cruz R, Cuezva JM, Cuscó I, Dalmau J, Cima S, Luna S, De Luna N, Oyarzabal Sanz A, Campo M, Castillo I, Molina LDP, Pozo ÁD, Río M, Delmiro A, Desviat LR, Dierssen M, Domínguez‐González C, Domínguez‐Ruiz M, Dopazo J, Errasti E, Escámez MJ, Estañ MC, Esteban J, Estévez R, Ezquieta B, Fernández L, Fernández A, Fernández‐Cancio M, Fernàndez‐Castillo N, Jose PF, Fillat C, Fons C, Fort J, Fourcade S, Fraga MF, Gallano P, Gallardo E, García M, García‐Arumí E, García‐Bravo M, García‐Cazorla A, García‐Consuegra I, Garcia‐Garcia FJ, García‐García G, García‐Giménez JL, Garcia‐Gimeno MA, García‐Miñaur S, García‐Redondo A, García‐Silva MT, García‐Villoria J, Santiago FG, Garrabou G, Garrido G, Garrido‐Pérez N, Gaztambide S, Gil‐Campos M, Giroud‐Gerbetant J, Glover G, Gómez B, Gómez‐Puertas P, Gonzalez‐Cabo P, Gonzalez‐Casacuberta I, Pozo MG, González‐Quereda L, González‐Quintana A, Gort L, Gougeard N, Gratacos E, Grau JM, Grinberg D, Güenechea G, Guerrero R, Guillén‐Navarro E, Guitart‐Mampel M, Gutiérrez‐Arumí A, Heath K, Heredia M, Hernández‐Chico C, Herreras E, Hoenicka J, Homs A, Jimenez‐Estrada JA, Jimenez‐Mallebrera C, Jou C, Juarez‐Flores DL, Lapunzina P, Larcher F, Lasa A, Lassaletta L, Latorre‐Pellicer A, Linares D, Llacer JL, Llames S, Lopez‐Gallardo E, López‐Laso E, López‐Lera A, Lopez‐Lopez D, López‐Sánchez M, Heredia ML, Granados EL, Lorda‐Sanchez I, Lozano ML, Luque J, Madrigal I, García CM, Mansilla E, Marco‐Marín C, Marfany G, Marina A, Martí R, Martí S, Martin Y, Martín MA, Martín‐Hernandez E, Martin‐Merida I, Martínez R, Martínez‐Azorín F, Martinez‐Delgado B, Martínez‐Gil N, Martínez‐Glez VM, Martínez‐Momblán MA, Martínez‐Romero MC, Fernández PM, Santamaría LM, Martorell L, Meade P, Meana Á, Medina MÁ, Mendes I, Méndez‐Vidal C, Millán JM, Minguez P, Minguillón J, Mirra S, Molla B, Moltó E, Montero R, Montoliu L, Montoya J, Morán M, Moren C, Moreno M, Moreno JC, Moreno‐Galdó A, Moreno‐Pelayo MÁ, Mori MA, Morin M, Morte B, Mulero V, Muñoz‐Pujol G, Murillas R, Murillo‐Cuesta S, Nascimento A, Navarro S, Navas P, Nevado J, Nicolas A, Nieto MÁ, O’Callaghan M, Olavarrieta L, Ormazabal A, Ortiz‐Romero P, Osorio A, Páez D, Palacín M, Palacios‐Verdú MG, Palau F, Palencia‐Campos A, Pallardó FV, Palomares M, Peña‐Chilet M, Pérez B, Perez‐Florido J, Pérez‐García D, Perez‐Jimenez E, Pérez‐Jurado LA, Perkins JR, Perona R, Pie J, Pinós T, Pinto S, Potrony M, Puig S, Puig‐Butille JA, Puisac B, Pujol R, Pujol A, Quintana Ó, Rabionet R, Ramos FJ, Ranea JAG, Reina‐Castillón J, Resmini E, Ribes A, Rica I, Richard E, Riera P, Río P, Riveiro‐Alvarez R, Rivera J, Rivera‐Barahona A, Robledo M, Rodriguez‐Aguilera JC, Rosa LR, Rodríguez‐Palmero A, Rodriguez‐Pombo P, Rodriguez‐Revenga L, Rodríguez‐Santiago B, Rodríguez‐Sureda V, Alba MR, Cordoba SR, Romá‐Mateo C, Rubio V, Ruiz Á, Ruiz M, Ruiz‐Arenas C, Ruiz‐Perez VL, Ruiz‐Pesini E, Ruiz‐Ponte C, Rullo J, Sabater L, Salazar J, Salido E, Sanchez‐Jimeno C, Cuesta AMS, Soler MJS, Santacatterina F, Santamarina M, Santos A, Santos‐Ocaña C, Simarro FS, Sanz P, Sastre L, Schlüter A, Segovia JC, Segura‐Puimedon M, Seoane P, Serra‐Juhe C, Serrano M, Serratosa JM, Sevilla T, Surrallés J, Tahsin‐Swafiri S, Tell‐Martí G, Tenorio‐Castaño JA, Tizzano E, Tobias E, Tort F, Trujillano L, Trujillo‐Tiebas MJ, Ugalde C, Ugarteburu O, Urreizti R, Urrutia I, Valencia M, Vallcorba P, Vallespín E, Varela‐Nieto I, Vega A, Vélez‐Santamaria V, Vílchez JJ, Villa O, Villamar M, Webb SM, Zubeldia JM, Zurita O. CIBERER: Spanish National Network for Research on Rare Diseases: a highly productive collaborative initiative. Clin Genet 2022; 101:481-493. [PMID: 35060122 PMCID: PMC9305285 DOI: 10.1111/cge.14113] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Revised: 01/13/2022] [Accepted: 01/13/2022] [Indexed: 11/30/2022]
Abstract
CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low‐prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15‐year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research.
Collapse
Affiliation(s)
- Juan Luque
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Ingrid Mendes
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Gómez
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Beatriz Morte
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Miguel López Heredia
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Enrique Herreras
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Virginia Corrochano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
| | - Juan Bueren
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz (IIS‐FJD), Madrid Spain
| | - Pía Gallano
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Genetics Department, Hospital de la Santa Creu i Sant Pau Barcelona Spain
- Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona Spain
- Universitat Autònoma de Barcelona Barcelona Spain
| | - Rafael Artuch
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Clinical Biochemistry Department, Institut de Recerca Sant Joan de Déu Barcelona Spain
| | - Cristina Fillat
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona Spain
- Universitat de Barcelona Barcelona Spain
| | - Luis A. Pérez‐Jurado
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Experimental and Health Sciences Universitat Pompeu Fabra (UPF), Barcelona Spain
- Genetics Service, Hospital del Mar Barcelona Spain
- Hospital del Mar Research Institute (IMIM), Barcelona Spain
| | - Lluis Montoliu
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Molecular and Cellular Biology, National Centre for Biotechnology (CNB‐CSIC), Madrid Spain
| | - Ángel Carracedo
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Grupo de Medicina Xenómica, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela Santiago de Compostela Spain
- Fundación Pública Galega de Medicina Xenómica (SERGAS), IDIS Santiago de Compostela Spain
| | - José M. Millán
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Unidad de Genética, Hospital Universitario y Politécnico La Fe Valencia Spain
- Biomedicina Molecular Celular y Genómica, Instituto Investigación Sanitaria La Fe Valencia Spain
| | - Susan M. Webb
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Hospital S Pau, Dept Medicine/Endocrinology, IIB‐Sant Pau, Research Center for Pituitary Diseases Barcelona Spain
- Departamento de Medicina Universitat Autònoma de Barcelona Barcelona Spain
| | - Francesc Palau
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- Department of Genetic and Molecular Medicine, Hospital Sant Joan de Deu Barcelona Spain
- Laboratory of Neurogenetics and Molecular Medicine ‐ IPER, Institut de Recerca Sant Joan de Déu Barcelona Spain
- Institute of Medicine & Dermatology, Hospital Clínic Barcelona Spain
- Division of Pediatrics University of Barcelona School of Medicine Barcelona Spain
| | - Pablo Lapunzina
- Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid Spain
- INGEMM‐Instituto de Genética Médica y Molecular, Hospital Universitario La Paz Madrid Spain
- Instituto de Investigación Sanitaria Hospital La Paz (IdiPAZ), Madrid Spain
- ERN‐ITHACA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Garcia Urbán J, Gurrado K, Brea Rivas PC, Abou Elrous D, Zubimendi Machain M, Romero Gómez M, García Rodríguez J, Vicandi Plaza B, Yébenes Gregorio L, García Fernández E, Jiménez Martín C, López Oliva MO, González García E, Ledesma Sánchez G, Carreño Cornejo G, Selgas Gutiérrez R, Zarauza Santoveña A, Melgosa Hijosa M, Fernández Camblor C, Mozo Del Castillo Y, Sisinni L, Bueno Sánchez D, Pérez-Martínez A, Sánchez Zapardiel E, López Granados E, Monserrat Villatoro J, Hernández Zabala R, Borobia AM, Frías J, Ramírez E. A case-control study to assess the role of polyomavirus in transplant complications: Where do we stand? Transpl Infect Dis 2020; 22:e13432. [PMID: 32738811 DOI: 10.1111/tid.13432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 07/22/2020] [Accepted: 07/24/2020] [Indexed: 11/27/2022]
Abstract
PURPOSE The study's aim was to assess whether polyomavirus DNAemia screening was associated with different outcomes in patients with positive viremia compared with negative viremia. METHODS Case-control retrospective study of patients with polyomavirus DNAemia (viremia > 1000 copies/mL) matched 1:1 with controls. Control group consists of the patient who received a transplant immediately before or after each identified case and did have nil viremia. FINDING Ultimately, 120 cases of BK polyomavirus (BKPyV) were detected and matched with 130 controls. Of these, 54 were adult kidney transplant recipients (KTRs), 43 were pediatric KTRs, and 23 were undergoing hemato-oncologic therapy, of which 20 were undergoing hematopoietic stem cell transplantation. The odds ratio (OR) for overall risk of poorer outcomes in cases versus controls was 16.07 (95% CI: 5.55-46.54). The unfavorable outcome of switching the immunosuppressive drug (ISD) (14/40,35%) was no different from that of those treated with reduced ISD doses (31/71, 43.6%, P = .250). Acute rejection or graft-versus-host disease, previous transplant, and intensity of immunosuppression (4 ISDs plus induction or conditioning) were risk factors for BKPyV-DNAemia (OR: 13.96, 95% CI: 11.25-15.18, P < .001; OR: 6.14, 95% CI: 3.91-8.80, P < .001; OR: 5.53, 95% CI: 3.37-7.30, P < .001, respectively). CONCLUSIONS Despite viremia screening, dose reduction, and change in therapeutic protocol, patients with positive BKPyV-DNAemia present poorer outcomes and unfavorable results.
Collapse
Affiliation(s)
- Julia Garcia Urbán
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Katia Gurrado
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Paola C Brea Rivas
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Dina Abou Elrous
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Mónica Zubimendi Machain
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - María Romero Gómez
- Microbiology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Julio García Rodríguez
- Microbiology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Blanca Vicandi Plaza
- Pathological Anatomy Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Laura Yébenes Gregorio
- Pathological Anatomy Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Eugenia García Fernández
- Pathological Anatomy Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Carlos Jiménez Martín
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - María-Ovidia López Oliva
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Elena González García
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Gabriel Ledesma Sánchez
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Gilda Carreño Cornejo
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Rafael Selgas Gutiérrez
- Nephrology Department, REDinREN, IRSIN, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | | | - Marta Melgosa Hijosa
- Pediatric Nephrology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Carlota Fernández Camblor
- Pediatric Nephrology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Yasmina Mozo Del Castillo
- Pediatric Hematology Oncology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Luisa Sisinni
- Pediatric Hematology Oncology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - David Bueno Sánchez
- Pediatric Hematology Oncology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Antonio Pérez-Martínez
- Pediatric Hematology Oncology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Elena Sánchez Zapardiel
- Immunology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Eduardo López Granados
- Immunology Department, IdiPaz, La Paz-Cantoblanco-Carlos III University Hospital, Madrid, Spain
| | - Jaime Monserrat Villatoro
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Rafael Hernández Zabala
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Alberto M Borobia
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Jesús Frías
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| | - Elena Ramírez
- Clinical Pharmacology Department, IdiPaz, School of Medicine, La Paz-Cantoblanco-Carlos III University Hospital, Autonomous University of Madrid, Madrid, Spain
| |
Collapse
|
8
|
Perez-Martinez A, Gasior M, Bueno D, Badell I, Sissini L, Torrent M, De Paz R, Granados EL, Querol S, Gimeno R. Naive T-Cell Depleted Allografts-Graft Engineered Hematopoietic Stem Cell Transplant in Pediatric Patients. Biol Blood Marrow Transplant 2018. [DOI: 10.1016/j.bbmt.2017.12.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Carrillo J, Calvete O, Pintado-Berninches L, Manguan-García C, Sevilla Navarro J, Arias-Salgado EG, Sastre L, Guenechea G, López Granados E, de Villartay JP, Revy P, Benitez J, Perona R. Mutations in XLF/NHEJ1/Cernunnos gene results in downregulation of telomerase genes expression and telomere shortening. Hum Mol Genet 2017; 26:1900-1914. [DOI: 10.1093/hmg/ddx098] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Accepted: 03/08/2017] [Indexed: 01/08/2023] Open
|
10
|
Chippirraz EL, Sorlí L, Montero M, Mas V, Granados EL, Vilaplana C, Alvarez-Lerma F, Knobel H, Horcajada JP. [Predictive factors for pneumonia in adults infected with the new pandemic A (H1H1) influenza virus]. Rev Esp Quimioter 2011; 24:204-208. [PMID: 22173190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND On April 2009 a new A (H1N1) influenza virus was identified with a higher incidence of severe outcome in younger people, most of them with pneumonia. The objective of our study was to identify the predictive risk factors of pneumonia in patients with the new A (H1N1) influenza virus infection. METHODS Prospective cohort study of adults infected with the new A (H1N1) influenza virus, admitted in a universitary hospital, from june 2009 to January 2010. Pneumonia was defined as the presence of any pulmonary infiltrate of any distribution with no other evident cause, in the chest radiography. A comparative analysis was made with patients with A (H1N1) influenza without pneumonia. RESULTS 281 patients with influenza A (H1N1) were treated. Thirty of them (10.6%) had pneumonia and 11 (3.9%) required intensive care. The global mortality was 0.7%. For the comparative analysis, 42 patients with influenza A (H1N1) without pneumonia were analysed (20 hospitalized and 22 nonhospitalised). In the multivariate analysis, obesity (BMI>30), (OR: 3.8; IC 95%: 0.99-15.0), time since symptom onset until hospital admission (OR 1.34; IC 95% 1.04-1.72), serum C reactive protein levels (OR:1.10; IC 95%: 0.98-1.24) and serum IgG2 levels (OR:1.08; IC 95%: 1.0- 1.01), were identified as independent risk factors for pneumonia. CONCLUSION Obesity, delay in medical care and higher levels of C reactive protein and IgG2 were predictive factors for pneumonia in adult patients with A (H1N1) influenza infection.
Collapse
|
11
|
Pérez de Diego R, López Granados E, Ferreira Cerdán A, Fontán Casariego G, García Rodríguez MC. Kinase activity and XLA phenotypic variability. J Allergy Clin Immunol 2005; 115:205-6. [PMID: 15637572 DOI: 10.1016/j.jaci.2004.07.059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Abstract
Mutations in Bruton's tyrosine kinase (BTK) gene result in X linked agammaglobulinemia (XLA). Using Single Strand Conformation Polymorphism (SSCP) followed by direct sequencing 21 mutations were found in 27 patients with an XLA phenotype from 21 unrelated families. We identified 13 novel and 8 known mutations: seven missense (R288W, R544G, P566S, K430E; K374N, L512P, R544S), 5 nonsense (Q196X, Y361X, L249X, Q612X, Q466X), 2 deletions of one nucleotide (A207fsX216, Q612fsX648), 2 deletion-insertions (V219fsX227, K218fsX228), one insertion of two nucleotides (S572fsX587) and 4 point mutations in donor/acceptor splice sites (g.IVS1+1G>C, g.IVS6+5G>A, g.IVS10+1G>T, g.IVS13-1GG>CT). Carrier detection was performed in 18 mothers. Only in one case the mutation was found to be de novo. Additionally, BTK mutations were not found in four patients without family history, but with XLA-compatible phenotype. Hum Mutat 18:84, 2001.
Collapse
|